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Background: Mutations in dysferlin, the first protein linked with the cell membrane repair mechanism, causes a group
of muscular dystrophies called dysferlinopathies. Dysferlin is a type two-anchored membrane protein, with a single C
terminal trans-membrane helix, and most of the protein lying in cytoplasm. Dysferlin contains several C2 domains and two
DysF domains which are nested one inside the other. Many pathogenic point mutations fall in the DysF domain region.
Results: We describe the crystal structure of the human dysferlin inner DysF domain with a resolution of 1.9 Ångstroms.
Most of the pathogenic mutations are part of aromatic/arginine stacks that hold the domain in a folded conformation.
The high resolution of the structure show that these interactions are a mixture of parallel ring/guanadinium stacking,
perpendicular H bond stacking and aliphatic chain packing.
Conclusions: The high resolution structure of the Dysferlin DysF domain gives a template on which to interpret in detail
the pathogenic mutations that lead to disease.
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Dysferlinopathies are a group of autosomal recessive inher-
ited late onset progressive muscular dystrophies caused by
malfunction of dysferlin protein. Mutations in the dysferlin
protein cause three phenotypes called limb girdle muscular
dystrophy type 2B [1], Miyoshi myopathy [2], and distal an-
terior compartment myopathy [3]. Dysferlin is not a part of
the dystrophin-glycoprotein complex, but its function is
linked with calcium-activated membrane repair caused by
fusing aggregated intracellular vesicles with the sarcolemma
at the site of injury [4-6]. The mechanism of membrane re-
pair is not yet determined in detail and the specific role of
dysferlin needs to be defined at the structural level.
Dysferlin, a member of the ferlin protein family, is a type
II anchored membrane protein with a single C terminal
helix buried in the membrane. Ferlin proteins are defined
as containing four or more C2 domains and a C terminal
trans-membrane helix. There are 6 ferlin proteins expressed
in human; dysferlin, myoferlin, otoferlin, Fer1L4, Fer1L5,
and Fer1L6 [7]. Myoferlin is the most similar paralogue to
dysferlin. Both proteins are predicted to have the same* Correspondence: n.keep@mail.cryst.bbk.ac.uk
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stated.domain composition with overall sequence identity of 56%.
Dysferlin is expressed in most tissues but is found in abun-
dance in skeletal muscle, heart, brain and placenta.
The multiple domain architecture of dysferlin was ana-
lysed by a combination of Gene3D [8], SMART [9] and
Pfam [10] domain family resources. The domain archi-
tecture is predicted to consist of seven C2 domains
(C2A to C2G), three Fer domains (FerA, FerB and FerI),
two DysF domains, one nested inside the other, and a C
terminal trans-membrane domain (Figure 1a). C2 domains
are found in hundreds of proteins and many are known
to bind to phospholipids or proteins, often in a calcium
dependent manner [6]. In dysferlin and myoferlin C2A
binds to phospholipids in a calcium dependent manner.
[11,12]. The other C2 domains do not show calcium-
dependent binding to lipids, but do show some calcium
independent binding to phospholipids [11,12]. The other
C2 domains are believed to interact with dysferlin binding
proteins or to be involved in dimerisation [13]. Recently it
has been shown that there is a minor variant of the dysfer-
lin C2A domain, C2Av1, that does not bind via calcium
[14]. Crystal structures of the canonical and variant struc-
tures of C2A show conservation of structure, even where
the sequence is not conserved. Biophysical characterisa-
tion of the interactions with phospholipids and calcium. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Domain organisation of dysferlin and alignment of DysF domains. a) Multiple domain architecture of human dyferlin protein
(Gene3D and pFam). b) Multiple sequence alignment of inner and outer DysF domain of Human Myoferlin, Dysferlin, Fer1l5; human Tecpr1 DysF
domains; inner and outer DysF domain of C. elegans FerI protein, and Yeast Pex30 DysF domain (aligned with mafft and drawn with ESPript).
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formationally flexible [14]. The Fer domains (FerA, FerB,
and FerI) are short conserved regions found only in the
ferlin protein family and are not yet shown to be folded
domains.
Dysferlinopathy causing mutations are dispersed through-
out the length of the protein, but many fall in the DysF
domains [15,16]. One DysF domain is inserted into the
other DysF domain, by gene duplication, forming an inner
DysF domain and a two part (N terminal and C terminal)
outer DysF domain [17]. The function of the DysF domain
is unknown. The human myoferlin (dysferlin paralogue)
inner DysF domain structure was solved by Nuclear
Magenetic Resonance (NMR) and showed a novel fold.
This consists of two long beta strands connected by a long
loop that caps the sheet edges in certain sections [18]. The
structure contains arginine/tryptophan stacks that holds
the fold together and are largely conserved throughout
DysF domain sequences (Figure 1b).
In this study, we have determined the three dimensional
structure of human dysferlin inner DysF domain by X-ray
crystallography at 1.9 Å. This is the first DysF domain crys-
tal structure.
Results and discussion
Structure characterisation
The structure was solved by molecular replacement with
the NMR structure of the inner DysF of myoferlin [18].
The sequence identity between the inner DysF domainin dysferlin and myoferlin is 61% (Figure 1b). Most datasets
that were collected, processed and refined in space group
P213 (cubic), with the best resolution dataset diffracting to
1.9 Å. A single dataset was collected in a different space
group P212121 (orthorhombic) to 2.2 Å. The crystal pack-
ing is almost the same in the two forms, but the distortions
of the perfect cube in the orthorhombic structure means
the monomers of the crystallographic trimer in the cubic
crystals are no longer identical (Figure 2a, b). This leads to
some of the flexible regions (eg residues 965-671) being
more visible in some chains with the orthorhombic data.
Except where stated otherwise the analysis is based on the
single chain in the 1.9 Å structure. Statistics for both data-
sets are summarised in Table 1 and have been deposited in
the Protein Data Bank [PDB:4CAH][PDB;4CAI].
The inner DysF domain construct starts at residue
Met942 and ends at Gln1052 and has a Ser on the N
terminus from the TEV protease site. The additional Ser,
Met942 and Gln1052 are not visible in the structures. The
main secondary structure consists of two long antiparallel
β-strands, one at each terminus (N terminus 946-958, C
terminus 1036-1049). These β-strands are connected with
a long loop (77 residues). The loop caps the edge of the N
terminal β-strand with main chain hydrogen bonds from
residues 966, 971 and 973. The C terminal β-strand is
capped with main chain hydrogen bonds from residues
993, 995, 996, 1000, 1013 and 1015. These give short β
strands within the linking loop. There is also a single
turn of 310 helix from 983 to 986 (Figures 1b, 2a). This
Figure 2 Comparison of DysF domain structures. Ribbon presentation of a) P213 asymmetric unit (the beta strands are coloured in yellow,
3 turn in pink, 4 turn in tan and no structure in grey) and b) P212121 asymmetric unit coloured by chain. c) Superimposed models of myoferlin
NMR DysF domain (blue) with dysferlin crystal DysF domain (red). d) Two areas of very high B factor in dysferlin DysD domain coloured in blue
(965-971) and red (1018-1021). Orientation as in Figure 2a). Figure drawn with CCP4mg [19].
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ture of the myoferlin inner DsyF domain [18].
The structure is highly conserved between independ-
ent copies in the crystals. The crystallographic trimer of
the P213 crystal superimposes onto the trimer in the
P212121 asymmetric unit with an RMSD Calpha of 0.89 Å
over 326 residues of the trimer. The four individual chains
from the two assymetric units superimpose no worse than
0.79 Å Calpha RMSD over 108 residues for any pair. The
conservation with the NMR structure of myoferlin is also
extremely high with a Calpha RMSD of 1.78 Å over 106
residues being the worst and 1.45 Å over 103 residues be-
ing the best of the 20 models (Figure 2c). The biggest vari-
ation between dysferlin models is between 965 and 971
and 1018 and 1021 (Figure 2d). These are also the regionswith the highest temperature (B) factors in dysferlin, the
regions with the largest RMS between NMR models in
myoferlin, as can be seen from the CING database [20,21],
and the regions that differ most between dysferlin and
myoferlin. However the region from 958-960 also has high
B factors, while conserving the backbone trace between
structures quite well.
The trimer (with 9 phosphates) is predicted to be the
stable assembly by PDBePISA [22]. Formation of the as-
sembly buries a total 5250 Å2. The interface between the
protein chains (repeated 3 times in the trimer) forms 5
(pisa) - 7(ccp4mg) hydrogen bonds and 3 salt bridges.
Three of these are mainchain-mainchain, with β3 for-
ming intermolecular β strand links to β1 as well as the
intramolecular H bonds to β6. 2 H bonds are mainchain-
Table 1 Data collection and refinement statistics of the
dysferlin inner DysF domain
Data collection PDB 4CAI PDB 4CAH
Wavelength (Å) 1.037530 0.97718
Space group P212121 P213
Unit-cell parameters
a, b, c (Å) 74.5, 77.47, 79.89 75.95, 75.95, 75.95
α, β, γ (o) 90, 90, 90 90, 90, 90
Resolution range (Å) 50-2.2 (2.27-2.20) 53.7-1.9 (1.94-1.9)
Total number of observation 78153 (6922) 115092 (7574)
Total number unique 24062 (2084) 11803 (760)
Completeness 99.8 (99.9) 100.0 (100.0)
Multiplicity 3.2 (3.3) 9.8 (10)
<I/σ(I)> 12.4 (2.3) 30.5 (3.5)
CC(1/2) 0.976 (0.758) 1.00 (0.847)
Rmerge 0.045 (0.466) 0.044 (0.667)
Solvent content (%) 56.8 53.0
Molecule per ASU 3 1
Wilson B factor (Å2) 42.2 31.05
Refinement
Resolution range (Å) 44.57-2.2 53.7-1.9
Rwork 0.1858 (0.2457) 0.1775 (0.1932)
Rfree 0.2271 (0.3102) 0.1908 (0.2283)
Reflection, working 22764 11220
Reflection, free 1206 549
Average B factor 61.0 42.0
Rmsd bond angle 1.358 1.76
Rmsd bond length (Å) 0.011 0.015
Ramachandran Analysis
Preferred region (%) 96.7 95.2
Allowed region (%) 2.4 2.9
Outliers (%) 0.9 1.9
Values in parentheses refer to the highest resolution shell.
Rmerge = Σ (I - < I>) / Σ < I > .
Rwork = Σ (|Fobs |- |Fcalc|)/ Σ|Fobs| for 95% of data. Rfree is the same equation for
5% of the data excluded from refinement.
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the formation of β3 is probably driven by the trimerisation.
The relatively low B factor in this side of the loop may
be partially caused by this packing. We have no evi-
dence from gel filtration or NMR spectroscopy (data
not shown) for the existence of a trimer, nor is there any
likely way to invoke a trimer in vivo. There are two DysF
domains in dysferlin and the reported oligomeric state
of the full length protein is a dimer. Therefore two or
four DysF domains seems more likely higher order as-
semblies, although extending the beta sheet either with
other DysF domains or other proteins does seem to be a
likely method of interaction.Arginine/tryptophan (R/W) stacks
As reported for the myoferlin inner DysF domain [18], the
dysferlin DysF domain is held together by arginine/aro-
matic sidechain stacking. Superficially there is a stack of
arginines and tryptophans which runs the entire length of
one face of the beta sheet, and a single small group on the
other face (Figure 3a). However, at the good resolution of
these crystal structures, we can give a much confident de-
scription of the exact nature of the interactions. In par-
ticular arginines can interact with aromatics either in a
stacked (ie with the guanadinium parallel to the aromatic
ring- above the six membered ring) [23] or in an H bond
(with the amino group pointing at the ring and the guana-
dinium plane perpendicular to the aromatic ring). Theor-
etical calculations favour the H bond arrangement in
vacuum but the stacked arrangement in water [24]. We
do see both these types of interaction but a number of the
arginine-guanadinium groups do not lie above the centre
of aromatic ring. In fact the atlas of sidechain interactions
[25,26], does not have the Arg –Trp pairs above the centre
of the ring in most of the clusters. Only one cluster lies
above the 6 membered ring. In four of the six cases the
guanadiniums lie above or beyond the NE-CZ containing
edge of the ring and in one case beyond the opposite edge
of the indole. In these cases there is still a hydrophobic
interaction of the aliphatic sidechain with the ring and the
guanadinium is available to form other H-bonds. A work-
ing definition of aliphatic stacking is that at least two side
chain atoms are within 3.8 Å of Trp ring atoms (the CH2-
CHar Van der Waals radii add up to 3.74 Å [27]).
The details of the R/W interactions are laid out in Table 2
and examples shown in Figure 3. The analysis shows that
in fact there is not one continuous stack, but three on one
face of the sheet. R1046 is to one side of W994, with only
one non-H atom within 3.8 Å. Instead Cys988 forms an
aromatic H bond interaction with W994. The second break
occurs between, R1040 and W1042, where both side chains
hydrogen bond to E955, but there is no direct interaction
between the two. On the other face R1039 stacks with both
F954 and W1027. Most but not all the stacking interactions
are conserved in the myoferlin inner domain, but the NMR
structure does not define which mode of packing is taking
place. By sequence homology most of these interactions
would be found in the dysferlin outer dysf domain
(sequence identity 32%). The inner dysf domain of myofer-
lin lacks equivalents of K983 and W1042, although the
overall fold is well conserved; conversely the outer dysferlin
dysF domain lacks an equivalent of C988 and R1048, so in
both cases the stacks will be a bit shorter.
Dysferlinopathy mutations
There are 15 missense mutations in the inner dysferlin
domain reported in the Leiden dysferlin mutation data-
base [15,16]. These are summarised in Table 3 which
Figure 3 The aromatic/arginine stack motif. a) Stick representation of the residues involved in W/R stacks; arginines and lysines are coloured
blue, aromatic residues are coloured green, and one cysteine residue in brown. Three forms of stack formation: b) parallel (W1012/R1038/W965),
c) perpendicular (R1046/W992), and d) aliphatic stacking (R1040/W1012). Maps are 2mFo-DFc from Phenix.refine contoured at 1.03 Sigma. Figure
drawn with CCP4mg [19].
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all the point mutations and close up views of the three
most reported mutations. The three most frequent
mutations disrupt the R/W stacks and are likely to
lead to a less stable or possibly unfolded domain. The
unfolded domain may lead to degradation of the en-
tire dysferlin protein. It is also notable that there are
several surface residues mutated, although in this very
flat domain nearly every residue contributes to the
surface, which may indicate that the DysF domain is
involved in protein-protein interactions.
Conclusions
The structure of the inner DysF domain of dysferlin
confirms the unusual fold of this domain first seen in
the myoferlin homologue. The high resolution of the
structure allows detailed analysis of the interactions
forming the R/W stacking seen in this domain. It also
provides a better model for understanding the disease
causing point mutations in this domain seen in dys-
ferlin patients. The most common mutations will dis-
rupt the R/W stacking, making the domain more
unstable or inherently unfolded, probably enhancing
the degradation of the protein. Some of the dysferlin
mutants map to the surface, implying that protein-
protein interactions may have a role in the function
of this domain.Methods
Protein preparation
Human dysferlin cDNA (Jain Foundation) was used to
amplify the DNA encoding for the residues 943-1052.
The human dysferlin inner DysF domain was cloned into
pNic28Bsa4 plasmid (supplied by Dr Opher Gileadi of
the Structural Genomics Consortium), which is a modi-
fied pET28a plasmid that allows ligation independent
cloning [48]. The vector contains an N terminal histidine
tag followed by a TEV protease cleavage site. The cloned
sequence was confirmed by DNA sequencing and the
plasmid transformed into E. coli strains Rosetta 2 (DE3)
cells. One fresh colony was inoculated into 100 ml of
Luria Broth media (LB) and the culture was grown over-
night. 8 × 500 ml of LB were inoculated with 1% of over-
night culture and incubated at 37°C until the optical
density reached 0.5 at a wavelength of 600 nm. Then the
cultures were induced with 0.5 mM of IPTG and incubated
at 18°C for 20 hours. Cells were collected by centrifuging at
4°C at 4000 rpm for 20 minutes and resuspended in bind-
ing buffer (20 mMTris, pH 7.5, 500 mM NaCl, 20 mM
imidazole, 10 mM 2-mercaptoethanol). The cells were
stored at -20°C. After incubating with EDTA free protease
inhibitor cocktail (Roche Applied Science, Switzerland),
0.1% Triton X-100 and DNAseI on ice for 30 minutes, the
cells were sonicated at 20 W output for 4 minutes of 4
second on/off pulses for three cycles on ice and then
Table 2 Aromatic arginine stack interactions in DysF domains
Stack Dysferlin
inner domain
W/R type Interactions Myoferlin inner domain equivalent
(Residue mentioned in interaction)
Outer Dysferlin
DysF equivalent
1 R1048 Aliphatic W992 Planar interaction to Y1034 in
crystal contact
K1029 P1100
H Bond to Q1010 in crystal
contact
Interacts with crystallisation
phosphate
Guanadinium Beyond NH/CZ
of W992
1 W992 H bonds to crystallisation
phosphate
W973 W924
1 R1046 Perpendicular W992 NH points to 6 membered ring
of W992
R1027 R1096
H bonds to crystallisation
phosphate
H bond to E951 (D392) (A879) ?E880
2 C988 H bond to 5 membered ring
of W994
C969 P920
W994 W975 W926
R1044 Planar W994/
Aliphatic W999
Planar stack above 5 membered
ring W994
R1025 R1096
2 W999 R1044 guanadinium is beyond NE/
CZ edge
W980 W930
Aliphatic interaction with side
chain of K983
2 K983 Just over 4 Å above 6 membered
ring of W1042
P964 K915
2 W1042 H bond to E955 L1023 (Q936) W1094 (E883)
3 R1040 Aliphatic W1012 H bond to E955 R1021 (Q396) R1092 (E883)
Guanadinium Beyond NE-CZ of
W1012
3 W1012 W993 W1069
3 R1038 Planar W1012 Planar stack to 5 membered ring
of W1012
R1019 R1090
Planar W965 Planar stack to 5 membered ring
of W965
3 W965 H bond to major conformation of
E1031
W946 (E1012) W894
3 R959 Aliphatic W965 Guanadinum Beyond NE-CZ of
W965
R940 K887
H bonds to major and minor
conformations of E1031
Opposite Face F954 Y935 Y882
R1039 Planar F954 Close to planar Stack above F954 R1020 R1090
Planar W1027 H bond to E1013 (E994) (E1070)
Planar Stack above 5 membered ring
of W1027 closer to NE than centre
W1027 W1008 Unclear
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was applied to a HisTrap (GE Healthcare) affinity col-
umn. The column was washed with binding buffer for10 column volumes and the protein eluted in 20 mM
Tris, pH 7.5, 500 mM NaCl, 500 mM Imidazole, 10 mM
2-mercaptoethanol buffer. The eluents containing the
Table 3 List of pathogenic missense mutations in the inner dysF domain taken from the Leiden database [16]
Residue Disease Number of reports References Role of residue Conservation score
Arg959Trp LGMD2B & MM 25 [28-34] In Stack 3 0.522
Met968Leu LGMD2B 1 [35] In loop. Poorly defined in structure and surface exposed 0.281
Trp992Arg LGMD2B & MM 2 [36] In Stack 1 1.000
Trp999Cys LGMD2B & MM 24 [35-40] In Stack 2 1.000
Glu1009Lys ? 1 [16] Surface exposed in loop. Close to phosphate in crystal 0.411
Gly1011Arg DACM 1 [32] Surface exposed in a loop 0.773
Tyr1014Cys LGMD2B & MM 5 [37,41] Orientates Arg1038 in Stack 3. H bond OH to guanadinium 1.000
Arg1022Gln LGMD2B 7 [28,37] Surface exposed. Poor side chain density 0.312
Pro1029Leu MM 2 [42] Surface exposed 0.062
Arg1038Gln LGMD2B 7 [28,29,42,43] In stack 3 1.000
Arg1039Trp MM 1 [16] Opposite face stack 0.923
Arg1039Leu MM 1 [44] Opposite face stack 0.923
Arg1041Cys MM 2 [31] Surface exposed. H bond to E952 0.617
Arg1044Ser DAMT 2 [44] In Stack 2 1.000
Arg1046His MM 11 [42,45,46] In Stack 1 0.386
LGMD2B- Limb Girdle Muscular Dystrophy 2B. MM-Myoshi Myopathy, DAMT-Distal anterior Myopathy Tibial Onset, Conversation Score was calculated using
alignment in Figure 1 and Scorecons program [47].
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TEV protease for 20 h at 4°C to remove the histidine
tag. Then the volume was decreased to 4 ml by Vivaspin
concentrator (Sartorius, Germany) with 5,000 Da mo-
lecular weight cutoff. The sample was further purified
by size exclusion chromatography using Superdex 200
16/60 column (GE, Healthcare). The protein was purifiedFigure 4 Missense mutations mapped onto DysF domain structure. (a
about the y axis of the page; mutated residues implicated in stack formatio
stabilising the arginines involved in stack formation (yellow). Other residues
most common pathogenic mutations (R959, W999 and R1046). H bonds sh
lines. Figure drawn with CCP4mg [19].further by anion exchange chromatography (Resource Q)
on a gradient of 0-0.5 M NaCl in 20 mM Tris, pH 7.5,
and 5 mM 2-mercaptoethanol. The protein concentra-
tion was estimated using NanoDrop spectrophotometer
at UV light absorbance at 280 nm (absorbance coef-
ficient = 45950 M-1 cm-1). The protein sample was
concentrated to 10 mg/ml (750 μM) in final bufferand c) Ribbon representation showing W/R stack rotated 180 degrees
n (red), mutated residues in the surface (blue), mutated residues
of the W/R stack are in green. (b): Interaction and environment of the
own as black dotted lines and stacking interactions as magenta dotted
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2-mercaptoethanol) and used for crystallisation trials.
Protein crystallisation and structure determination
The inner DysF domain was screened for crystallisation
at 16°C, by the sitting-drop method in 96- well crystal-
lisation plates (Molecular Dimensions), using PACT
screen [49]. After 11 days, small crystals appeared in a
drop with mother liquor consisting of 0.2 M NaBr and
20% PEG 3350. This crystallisation could not be repro-
duced initially. 0.2 M NaBr was then added to the pro-
tein sample and the crystallisation screen was done
again. Bigger crystals were produced in one day, where
the reservoir contained 0.04 M potassium dihydrogen
phosphate, 16% w/v PEG 8000 and 20% v/v Glycerol.
0.3 mm cubic crystals were grown by the hanging drop
method based on this condition. The crystal was cryo-
protected in crystallisation buffer with the glycerol
concentration increased to 25%. Initial diffraction
data was collected to 2.3 Å in house using MicroMax
TM -007 rotating anode X-ray generator (λ = 1.54 Å)
and Saturn 944+ CCD detector with Varimax optics.
Further data was collected at Soleil beamline proxima
1 and at beam ID29 at ESRF. Diffraction images were
processed using XDS software package [50], and
scaled using aimless in the CCP4 program suite [51].
The initial phases of the dysferlin inner DysF domain
were determined by molecular replacement with the
program Mr Bump [52] using human myoferlin inner
DysF domain [18] [PDB:2K2O] as the search model.
The model was manually rebuilt in COOT [53] and
refined initially in Refmac [54] and then continued in
PHENIX [55]. Data collection and refinement statis-
tics are summarized in Table 1.
No human subjects were directly used in this study.
Human mutation data was taken from publicly access-
ible databases.
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